Nirmatrelvir/Ritonavir Regimen for Mild/Moderately Severe COVID-19: A Rapid Review With Meta-Analysis and Trial Sequential Analysis
GN Okoli, N Askin, R Rabbani - The Annals of Family Medicine, 2024 - annfammed.org
BACKGROUND The efficacy, effectiveness, and safety of the approved nirmatrelvir/ritonavir
regimen for treatment of laboratory-confirmed mild/moderately severe COVID-19 remains …
regimen for treatment of laboratory-confirmed mild/moderately severe COVID-19 remains …
The impact of vaccination and outpatient treatment on the economic burden of COVID-19 in the United States omicron era: a systematic literature review
V Pierre, F Draica, M Di Fusco, J Yang… - Journal of Medical …, 2023 - Taylor & Francis
Aims To identify and synthesize evidence regarding how coronavirus disease 2019 (COVID-
19) interventions, including vaccines and outpatient treatments, have impacted healthcare …
19) interventions, including vaccines and outpatient treatments, have impacted healthcare …
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
S Ombelet, D Castanares‐Zapatero… - Journal of medical …, 2024 - Wiley Online Library
Nirmatrelvir‐ritonavir (NR) was approved to treat SARS‐CoV‐2 positive outpatients at high
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …
A review on the impact of the SARS-CoV-2 Omicron subvariant on elderly patients with diverse co-morbidities
The SARS-CoV-2 virus has caused a catastrophic impact on the world for the past 3 years.
The virus has now returned with the emergence of the Omicron (B. 1.1. 529) variant. Within …
The virus has now returned with the emergence of the Omicron (B. 1.1. 529) variant. Within …
Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2, Update Alert)
This first update alert reports surveillance results of the living, rapid evidence review on
“Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the …
“Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the …
Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or …
F Bai, T Beringheli, V Vitaletti, A Santoro, F Molà… - Infectious Diseases and …, 2024 - Springer
Introduction We compared the effectiveness and virological clearance (VC) at day 7 (T7)
post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2 …
post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2 …
Approaches to pandemic prevention–the chromatin vaccine
J Zhang, P Askenase, R Jaenisch… - Frontiers in …, 2023 - frontiersin.org
Developing effective vaccines against viral infections have significant impacts on
development, prosperity and well-being of human populations. Thus, successful vaccines …
development, prosperity and well-being of human populations. Thus, successful vaccines …
Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID‐19 patients with type 2 diabetes: A target trial …
Aims To compare the effectiveness of molnupiravir and nirmatrelvir‐ritonavir for non‐
hospitalized and hospitalized COVID‐19 patients with type 2 diabetes (T2DM). Materials …
hospitalized and hospitalized COVID‐19 patients with type 2 diabetes (T2DM). Materials …
Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary …
N Shang, X Li, Z Guo, L Zhang, S Wang - Frontiers in Pharmacology, 2024 - frontiersin.org
Introduction: Numerous studies have explored the treatment outcomes of Nirmatrelvir-
Ritonavir and Azvudine in older patients with COVID-19. However, direct comparisons …
Ritonavir and Azvudine in older patients with COVID-19. However, direct comparisons …
[PDF][PDF] Nirmatrelvir-Ritonavir for the Treatment of COVID-19
The findings suggest nirmatrelvir-ritonavir reduces the risk of disease progression,
hospitalization, or death compared to placebo or standard of care in people with mild to …
hospitalization, or death compared to placebo or standard of care in people with mild to …